In September 2014, the medication CONTRAVE (naltrexone HCI and bupropion HCI) was approved for use in patients with a body mass index (BMI) of 30 (obesity) or more without weight-related medical conditions or a BMI of 27 or greater with a weight-related medical condition
His mission is to help patients reach their set pointa stable weight that supports energy, confidence, and overall wellness
This may lead to many of the same reported side effects as above, but may also come with complications like dehydration or malnutrition if left untreated
Pfizer Medical Information - Canada
Patients are losing weight at a faster rate than what weve seen with other types of obesity treatments, Jastreboff explains
Heres what usually happens in those early weeks: Reduced appetite Mild weight drop Better control of cravings Over time, a lot more change can be seen